Volume 34
Issue 3, 2014
ISSX President’s Message By John O. Miners, ISSX President This Newsletter focuses primarily on the 19th North American meeting of ISSX, which will be held jointly with the 29th Meeting of the Japanese Society for the Study of Xenobiotics (JSSX) in San Francisco in just a few weeks. This is our second joint meeting with JSSX – the first was held in Maui in 2005 and was a great success, attracting more than 1,100 registrants. The San Francisco meeting is dedicated to Professor Yuichi Sugiyama in recognition of his outstanding scientific contributions to the field of xenobiotic disposition. Professor Sugiyama is a past President of both JSSX and ISSX. As I have indicated previously, organizing high-quality scientific meetings and international outreach are core activities of ISSX – partnering with JSSX ticks both boxes. Professors Eric Johnson and Tetsuya Terasaki, the meeting co-chairs, and their colleagues on the Meeting Organizing Committee have put together an excellent scientific
program. The meeting begins on Sunday, October 19 with four short courses, followed by plenary lectures and the Welcome Reception. The sixteen symposia scheduled between Monday, October 20 and Thursday, October 23 address a diverse range of topics that include biomarkers, chronopharmacology, drug-drug interactions, drug metabolizing enzymes, genomics, humanized rodent models, metabolomics, PK-PD, systems biology, therapeutic antibodies, transporters, toxicology issues in drug discovery, and transcriptional and post-translational regulation. These symposia are complemented with poster sessions, industry-sponsored symposia, a comprehensive trade exhibition, and lectures from Professor Thomas Baillie and Dr Nina Isoherranen, the respective recipients of the North American Scientific Achievement Award (in honor of Ronald W. Estabrook) and the North American New Investigator Award (in honor of James R. Gillette).
Like the first JSSX-ISSX meeting, the San Francisco meeting promises to be highly successful. In addition to the invited lectures, symposia and short courses, there are 550 poster submissions and 55 companies will be presenting their latest products and services in the trade exhibition. The meeting promises to be rewarding, scientifically and socially. The main social event is a dinner cruise on the San Francisco Spirit. I hope that you will join us in San Francisco for a great meeting. John O. Miners President International Society for the Study of Xenobiotics
IN THIS ISSUE 1
ISSX President’s Message
2
Book Review: Enzyme Kinetics In Drug Metabolism
North American ISSX / 3 19th 29th JSSX Meeting
13
13th European ISSX Meeting
15 Welcome New Members
Book Review ENZYME KINETICS IN DRUG METABOLISM; Fundamentals and Applications. Editors: S Nagar, UA Argikar, DJ Tweedie Humana Press 538pp, ISBN 13:978-1-62703-757-0,2014
2
/ISSX Newsletter / Issue 3, 2014
The book begins, as one would expect, with an introductory chapter in which the ethos of the volume is described together with a brief summary of the contents. The remainder is divided into five interrelated sections, each of which contains several chapters, and their titles are listed below so that the prospective reader may gain an insight into the coverage of this tome. Fundamentals of enzyme kinetics (Fundamentals of enzyme kinetics; Different enzyme kinetic models; Reversible mechanisms of enzyme inhibition and resulting clinical significance; Irreversible enzyme inhibition kinetics and drug-drug interactions; Multienzyme kinetics and sequential metabolism; Consideration of the unbound drug concentration in enzyme kinetics), Kinetics of drug metabolising enzymes and transporters (Enzyme kinetics of oxidative metabolism: Cytochromes P450; Enzyme kinetics, inhibition, and regioselectivity of aldehyde oxidase; Enzyme kinetics of conjugating enzymes: PAPS sulfotransferase; Enzyme kinetics of uridine diphosphate glucuronosyltransferses (UGTs); Principles and experimental considerations for in vitro transporter interaction assays), Modeling considerations (Rationalizing
underprediction of drug clearance from enzyme and transporter kinetic data: From in vitro tools to mechanistic modelling; A structural model for the mass action kinetic analysis of P-gp mediated transport through confluent cell monolayers; Systems biology approaches to enzyme kinetics: Analyzing network models of drug metabolism), Variability in kinetics (Variability in human in vitro enzyme kinetics; Sources of interindividual variability), Case studies (Practical considerations with experimental design and interpretation; Practical analytical considerations for conducting in vitro enzyme kinetic studies; Application of basic enzyme kinetics to metabolism studies: Real-life examples; Predicting the drug interaction potential for inhibition of CYP2C8 by montelukast; Deconvoluting hyperbilirubinemia: Differentiating between hepatotoxicity and reversible inhibition of UGT1A1, MRP2, or OATP1B1 in drug development; Transporter case studies: In vitro solutions for translatable outcomes; Compiled Aha moments in enzyme kinetics: Authors’ experiences).
information which is comprehensive, clearly explained, and pleasingly agreeable to read. Indeed, within the chapter concerning interindividual variability a fundamental point is made: “understanding the mechanistic basis for drug disposition and response variability is essential if we are to move beyond the era of empirical, trial-and-error dose selection and into an age of personalized medicine that brings with it true improvements in health outcomes in the therapeutic treatment of disease” (page 363). This is what we all hope for; perhaps an all-encompassing “systems biology/‘omic” approach will be fruitful here? A six page index containing double columns and four appendices explaining abbreviations, symbols, and a list of commonly employed enzyme kinetics equations enhance the tome. This is a worthwhile addition to anyone’s library and especially for those embarking upon or already involved within the area of enzymology and requiring practical advice and expedient protocols within this field.
This text is volume 1113 in the “Methods in Molecular Biology” series, which has been running for over 30 years, and as mentioned in the foreword, it “provides a very practical introduction to the basic principles of enzyme kinetics in drug metabolism and is an ideal resource for students at all levels, including scientists in academia and the pharmaceutical industry” (page vii). In this volume, the 44 contributors have assembled a wealth of
Steve Mitchell Faculty of Medicine Imperial College London London SW7 2AZ, UK
Reviewed by
Book ordering information: Humana Press Springer Science & Media, LCC 233 Spring Street New York NY 10013 Web: www.springer.com
ISSX 2015 MEMBERSHIP Support ISSX! Renew with ISSX for the 2015 Membership term and save on your meeting registration for the upcoming 19th North American / 29th JSSX Meeting in San Francisco, CA this October! www.issx.org/renew.
19th North American ISSX / 29th JSSX Meeting There is still time to pre-register for the 19th North American ISSX / 29th JSSX Meeting! Planning of the 19th North American ISSX and 29th JSSX Meeting, to convene October 19–23, 2014 in San Francisco, continues to advance and all indicators are pointing to a highly successful meeting with 550 poster abstracts, an exhibition hall with 55 companies presenting their latest products and services, eight industrysponsored symposia sessions, several award lectures, and much more. Dedicated to Professor Yuichi Sugiyama, the meeting will begin on Sunday, October 19 with short courses on DDI prediction, metabolite biosynthesis and structure determination, Non-CYP metabolism, and a tutorial on using database mining to maximize the use of DMPK and DDI data during clinical development of new chemical entities. The short courses will be followed by a welcome reception for all attendees and registered guests. The JSSX annual meeting and reception will be held on Saturday, October 18.
Hotel rooms at the Hilton San Francisco Union Square Hotel remain available but act quickly! Reserve accommodations online at https:// aws.passkey.com/ g/22337821 or dial 1 (415) 771-1400 and be certain to identify yourself as an attendee of our meeting. Located approximately 14 miles from San Francisco International Airport (SFO) and Oakland International Airport (OAK), the hotel is easily accessible by airport shuttle, public transportation, taxi, and rental car and features many services that will assuredly make your stay a pleasant one.
Schedule-at-a-Glance Saturday, October 18, 2014 1:00 p.m. – 7:00 p.m. Meeting Registration Open 4:00 p.m. – 6:00 p.m. Japanese Society for the Study of Xenobiotics President’s Lecture and Awards Ceremony 6:00 p.m. – 8:00 p.m. JSSX Reception
Sunday, October 19, 2014
Monday, October 20, 2014 7:30 a.m. – 5:00 p.m. Meeting Registration Open 7:45 a.m. – 8:45 a.m. Industry-Sponsored Symposia 9:00 a.m. – 11:30 a.m. Concurrent Symposia 11:30 a.m. – 2:00 p.m. Meet with Exhibitors / Lunch on Own 11:30 a.m. – 12:30 p.m. Poster Award Finalist Authors of A1 - A6 Present Posters 12:30 p.m. – 2:00 p.m. Authors of Posters P1 - P104 Attend and Present Posters
Continued on page 6
/ISSX Newsletter / 3
2:00 p.m. – 4:30 p.m. Concurrent Symposia 4:30 p.m. – 6:00 p.m. Authors of Posters P105 - P215 Attend and Present Posters 6:00 p.m. – 8:00 p.m. New Investigator’s Reception 7:00 p.m. – 9:00 p.m. JSSX and ISSX Presidents’ Reception (by invitation)
Issue 3, 2014
8:00 a.m. – 7:00 p.m. Meeting Registration Open 8:00 a.m. – 5:00 p.m. Exhibitor Set Up 8:00 a.m. – 9:00 a.m. Breakfast for Morning Short Course Attendees 9:00 a.m. – 12:00 p.m. Short Course 1 and Short Course 2 12:00 p.m. – 1:00 p.m. Lunch for Afternoon Short Course Attendees 1:00 p.m. – 4:00 p.m. Short Course 3 and Short Course 4 4:15 p.m. – 4:45 p.m. Opening Session
4:45 p.m. – 6:45 p.m. Opening Plenary Lectures 7:00 p.m. – 9:00 p.m. Opening Welcome Reception/ Meet the Exhibitors
More compounds. More accurately. Faster than ever. Today’s range of possible therapeutic agents, from small molecules to peptides, to antibodies and ADC’s, makes quantitative bioanalysis a challenge. Quantify potential therapeutics faster and more accurately with our new portfolio of LC-MS instruments, sample prep solutions and software. HRAM solutions using Thermo Scientific™ Orbitrap™ MS enables selectivity for complex molecules, while triple quadrupole MS delivers SRM sensitivity and speed to detect targeted compounds more quickly. Meet today’s challenges with us and together, we’ll transform quantitative bioanalysis.
Quantitation transformed.
© 2014 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries.
• Discover more at thermoscientific.com/quan-transformed
Thermo Scientific™ Orbitrap Fusion™ MS Unprecedented depth of analysis and throughput for biological discovery
Thermo Scientific™ Q Exactive™ MS Screen and quantify known and unknown targets with HRAM Orbitrap technology
Thermo Scientific™ TSQ Quantiva™ MS Leading SRM sensitivity and speed in a triple quadrupole MS/MS
Answers}Through}Innovation
Integrating Chemistry & Metabolism to Accelerate Your Product Development The largest radiolabelling group in the world combined with our expert metabolism team makes Quotient a winning choice }} Tritium}&}stable}isotope}synthesis }} Carbon}14}synthesis}including}} GMP}capabilities }} Drug-drug}interaction}assessment} (including}transporters) }} Pre-clinical}DMPK
}} Experts}in}metabolite}analysis} (profiling/identification) }} RadioTag:}PK/QWBA} biopharmaceuticals }} Synthesis-to-clinic™:}complete} clinical}metabolism}provider
metabolism@quotientbioresearch.com}
www.quotientbioresearch.com/metabolism
JOIN US FOR THE PREMIER SOCIAL EVENT OF THE MEETING A dinner cruise on the yacht San Francisco Spirit on Wednesday, October 22! View the city lights and architecture as you cruise the bay of San Francisco. Attendees will see the infamous Alcatraz Island with its former federal penitentiary, the magnificent Golden Gate Bridge, the art deco Coit Tower, the iconic Transamerica Building, and much more while enjoying an open bar and dinner buffet on the yacht. The yacht features three decks with heated indoor and outdoor areas, two marble dance floors, three bars, and plenty of windows to afford attendees with spectacular views. The dinner cruise is three hours long and motor coach transportation will be provided between the meeting hotel and Pier 3. Purchase your ticket through the meeting registration site at www.issx.org/enroll. We look forward to welcoming you to San Francisco for what is certain to be a highly educational and socially rewarding meeting.
19th North American ISSX and 29th JSSX Meeting Hilton San Francisco Union Square San Francisco, California, USA October 19–23, 2014
13th European Meeting University of Strathclyde Glasgow, Scotland, UK June 22–25, 2015
20th North American ISSX Meeting Hilton Orlando Bonnet Creek Orlando, Florida, USA October 17–21, 2015
/ISSX Newsletter / 5
UPCOMING MEETINGS
Issue 3, 2014
We hope you will join us for this unique event.
Tuesday, October 21, 2014 7:30 a.m. – 5:00 p.m. Meeting Registration Open 7:45 a.m. – 8:45 a.m. Industry-Sponsored Symposia 9:00 a.m. – 11:30 a.m. Concurrent Symposia 11:30 a.m. – 2:00 p.m. Meet with Exhibitors / Lunch on Own 11:30 a.m. - 12:30 p.m. Poster Award Finalist Authors of A7 - A12 Present Posters 12:30 p.m. – 2:00 p.m. Authors of Posters P216 - P318 Attend and Present Posters 2:00 p.m. – 3:00 p.m. ISSX Awards Session 3:00 p.m. – 5:30 p.m. Concurrent Symposia 5:30 p.m. – 7:00 p.m. Authors of P319 - P429 Attend and Present Posters
Visit BioreclamationIVT at Booth # 301 19th North American ISSX Meeting/29th JSSX Meeting
Register for a free vial of our NEW InVitroCYP™ 150-Donor Human Liver Microsome product Attend our Breakfast ISS Symposium on Monday, October 20th at 7:30 AM in the Imperial Ballroom Extreme Donor Variability in Human Aldehyde Oxidase Activity: Pharmacogenomics and In Vitro Solutions Speaker: J. Matthew Hutzler, Ph.D., Quintiles Check out our 4 Scientific Poster Presentations
/ISSX Newsletter / Issue 3, 2014
Learn More - LiverPool™ Cryopreserved Human Hepatocytes - Cryoplateable Human and Animal Hepatocytes - Human and Animal Blood, Plasma, Serum and PBMCs
7:30 a.m. – 5:00 p.m. Meeting Registration Open 7:45 a.m. – 8:45 a.m. Industry-Sponsored Symposia 9:00 a.m. – 11:30 a.m. Concurrent Symposia 11:30 a.m. – 2:00 p.m. Meet with Exhibitors / Lunch on Own 12:30 p.m. – 2:00 p.m. Authors of Posters P430 - P543 Attend and Present Posters 2:00 p.m. – 4:00 p.m. JSSX Awards Session 4:00 p.m. – 5:00 p.m. Poster Awards Competition Finalists Short Oral Presentations 5:00 p.m. – 5:15 p.m. Presentation of Poster Awards Competition Awards 6:00 p.m. – 10:00 p.m. Dinner Cruise on San Francisco Bay
Thursday, October 23, 2014 7:30 a.m. – 3:30 p.m. Meeting Registration Open 7:45 a.m. – 8:45 a.m. Industry-Sponsored Symposia 9:00 a.m. – 11:30 a.m. Concurrent Symposia 11:30 a.m. – 12:30 p.m. Lunch on Own 12:30 p.m. – 3:00 p.m. Concurrent Symposia 3:00 p.m. – 3:30 p.m. Closing Session / Meeting Adjourns
- Homogenate and Tissue Sample
For more details go to: www.bioreclamationivt.com/ISSX
For Inquiries:
6
Wednesday, October 22, 2014
North America T +1 516 483 1196 E info@bioreclamationivt.com
Continued on next page
Industry-Sponsored Symposia Industry-Sponsored Symposia (ISS) are commercially-supported educational and promotional activities held in conjunction with the 19th North American ISSX / 29th JSSX Meeting. Although not an official part of the meeting, these programs have been reviewed and these presentations permitted by JSSX and ISSX. If you are attending the 19th North American ISSX / 29th JSSX Meeting, make plans to participate in the morning Industry-Sponsored Symposia offered: Scheduled Industry-Sponsored Symposia Monday, October 20, 2014 | 7:45 a.m. - 8:45 a.m. | Concurrent Symposia
Thermo Scientific | Continental Ballroom
Bioreclamation IVT | Imperial Ballroom EXTREME DONOR VARIABILITY IN HUMAN ALDEHYDE OXIDASE ACTIVITY: PHARMACOGENOMICS AND IN VITRO SOLUTIONS Presented by: J. Matthew Hutzler, Ph.D.
Tuesday, October 21, 2014 | 7:45 a.m. - 8:45 a.m. | Concurrent Symposia
Hepregen Corporation | Continental Ballroom
HTG Molecular Diagnostics | Imperial Ballroom
CROSS-SPECIES COMPARISON OF METABOLITE PROFILES USING HepatoPac Presented by: Scott Obach, Ph.D., Pfizer, Inc.
A MULTIPLEX APPROACH TO INVESTIGATE DRUG INDUCED CHANGES IN P450 ENZYME EXPRESSION Presented by: Jason DeLoach and Mark Schwartz, Ph.D.
Wednesday, October 22, 2014 | 7:45 a.m. - 8:45 a.m. | Concurrent Symposia
Corning Incorporated | Continental Ballroom
Life Technologies| Imperial Ballroom NEW ADVANCES IN ORGANOTYPIC MODELS FOR ADME/TOX APPLICATIONS
Quotient Clinical| Imperial Ballroom
JAPANESE LATEST GUIDELINES ON DRUG-DRUG INTERACTIONS (DDI)
DEFINING A “GOLD STANDARD” FOR ESTABLISHING INTRAVENOUS PHARMACOKINETICS, HUMAN MASS BALANCE AND METABOLISM DATA FROM A SINGLE INTEGRATED STUDY AND A SINGLE REGULATORY SUBMISSION
Presented by: Guy Webber, Chief Scientist In Vitro
Presented By: Iain Shaw Continued on next page
/ISSX Newsletter / 7
Quotient Bioresearch | Continental Ballroom
Issue 3, 2014
Thursday, October 23, 2014 | 7:45 a.m. - 8:45 a.m. | Concurrent Symposia
ISSX and JSSX wish to thank these companies which are part of our meeting sponsorship program: Gold Level
‘Gold standard’ Human ADME studies Excellence in human PK and metabolism
Silver Level
} No human ADME data? } Low or variable bioavailability?
Bronze Level
} Pressing development or regulatory deadline?
Discover Synthesis-to-ClinicTM - delivering human ADME data as a seamless program of work Tightly integrated 14 supply chain C API Synthesis Preclinical Data Regulatory Affairs Drug Manufacture Clinical Conduct Bioanalysis Reporting
✓ Multidisciplinary service provider ✓ Single project manager ✓ Integrated Quality process ✓ Continuity of the science ✓ Removal of management burden
Empowered by Translational Pharmaceutics
New Investigator Reception
Name Badge Lanyards
Email Iain.Shaw@quotientclinical.com For further info, visit us at Booth 312 at ISSX/JSSX www.quotientclinical.com
Continued on next page
Enabling you to build more predictive cell models for toxicity analyses
ADME/Tox Sourcebook
We offer the most comprehensive portfolio of tools to support your workflow across every step. Visit us at booth #401 to see how we can Life ADME/Tox products help youTechnologies seamlessly integrate these powerful tools into your workflow. For Research Use Only. Not for use in diagnostic procedures. Š 2014 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. ISSX2014 0814
ISSX_ADME_Ad_f_08152014.indd 1
8/15/2014 8:43:40 AM
ISSX Honors Outstanding Members with Highest North American Awards North American Scientific Achievement Award in Honor of Ronald W. Estabrook, Sponsored by XenoTech
/ISSX Newsletter / 9
Continued on next page
Issue 3, 2014
The North American Scientific Achievement Award in Honor of Ronald W. Estabrook, Sponsored by XenoTech, is presented to an ISSX member who has made major scientific contributions to the field within the North America region. The purpose of this award is to recognize meritorious contributions by senior or mid-career scientists that have had a major impact on research in the field. The 2014 recipient is Thomas A. Baillie, Ph.D., D.Sc. of the University of Washington.
Dr. Baillie has made major contributions to our understanding of the metabolism of xeno- and endobiotics and is internationally-recognized for seminal contributions in this field. Dr. Baillie’s early contributions include studies of the formation of reactive metabolites of xenobiotics and drugs such as phencyclidine, allylisopropylacetamide, valproic acid, N-methylformamide, and acetaminophen. His investigation of the desaturation of valproic acid provides an example of his elegant use of isotope effects and mass spectrometry to characterize a novel, mechanistically important function of cytochrome P450 enzymes. His studies of the bioactivation of acetaminophen and its involvement in protein alkylation came at an early stage and helped to establish what has become the paradigm for the relationship between drug activation, glutathione depletion, protein alkylation, and toxicity. Dr. Baillie has played a major role in elucidation of the mechanism of the coenzyme A-dependent metabolic chiral inversion observed with agents such as ibuprofen. This record of creative
drug metabolism research has resulted in more than 200 original research papers in addition to many reviews and book chapters. Dr. Baillie is Professor of Medicinal Chemistry and Dean of the School of Pharmacy at the University of Washington in Seattle, Washington. He trained in Scotland and Sweden and began his academic career at the University of London. In 1978, Dr. Baillie took up a research appointment at the University of California Berkeley, and later joined the faculty at the University of California at San Francisco. He next spent fourteen years at the University of Washington School of Pharmacy before joining Merck as head of their global drug metabolism department. In 2008, Dr. Baillie returned to the University of Washington as Dean of the School of Pharmacy. To recognize and celebrate Dr. Baillie’s substantial contributions to the field of xenobiotic disposition including his service on the leadership of ISSX and other scientific societies, we proudly award him the 2014 North American Scientific Achievement Award in Honor of Ronald W. Estabrook. Award Presentation and Lecture: Tuesday, October 21, 2014 | 2:00 p.m. – 3:00 p.m. | Continental Ballroom
Meeting Organizing Committee Eric Johnson, PhD (Meeting Co-Chair), The Scripps Research Institute Tetsuya Terasaki, PhD (Meeting CoChair), Tohoku University Kan Chiba, PhD, Chiba University Frank Gonzalez, PhD, National Cancer Institute Natalie Hosea, PhD, Pfizer Inc. Takashi Izumi, PhD, Daiichi Sankyo Co., Ltd. Paul Ortiz de Montellano, PhD, University of California, San Francisco R. Scott Obach, PhD, Pfizer Inc. Bill Smith, PhD, Gilead Sciences Hiroshi Suzuki, PhD, The University of Tokyo Hospital Peter W. Swaan, PhD, University of Maryland Mikihisa Takano, PhD, Hiroshima University Ikumi Tamai, PhD, Kanazawa University
10
/ISSX Newsletter / Issue 3, 2014
North American New Investigator Award in Honor of James R. Gillette The 2014 North American New Investigator Award in Honor of James R. Gillette is presented to an ISSX member who has made significant contributions to the field during their early career years. The purpose of this award is to encourage and recognize a developing scientist who is active in the field in North America. The 2014 recipient is Nina J. Isoherranen, Ph.D., of the University of Washington. Dr. Isoherranen has established a solid research program that is focused primarily on the interaction of xenobiotics with (less well-known) enzyme systems such as CYP2D6 and ALDH1A2 that modulate retinoic acid homeostasis and thereby influence a variety of pharmacological processes. This work has included studies on potential
Toshio Teramura, PhD, Astellas Pharma, Inc. Hiroshi Yamazaki, PhD, Showa Pharmaceutical University Xiao-bo Zhong, PhD, University of Connecticut School of Pharmacy
agents for male contraception, drug candidates for the treatment of Alzheimer’s disease, and aspects of drug disposition during pregnancy, all of which are influenced by CYP26 and/or ALDH1A2 status. Dr. Isoherranen also has developed an interest in the role of inhibitory drug metabolites as mediators of complex, clinically relevant drug-drug interactions, such as those caused by the stereoselective inhibition of CYPs 2C19 and 3A4 by fluoxetine and norfluoxetine. Dr. Isoherranen ’s productivity in each of these areas is reflected by her impressive list of publications in the peer-reviewed literature, which now numbers almost 70 full papers, and by her success in attracting federal research support as Principal Investigator on NIH grants.
Continued on next page
Dr. Isoherranen earned a Ph.D. in pharmaceutical sciences at the Hebrew University of Jerusalem, Israel and completed postdoctoral training at the University of Washington School of Pharmacy in the Department of Pharmaceutical Sciences. She was promoted to faculty in 2006 and achieved the position of Associate Professor with tenure in 2012. During this time, Dr. Isoherranen has become recognized in the fields of drug metabolism and pharmacokinetics through the establishment of a diverse and productive research program. The overall theme of Dr. Isoherranen’s research has been the application of in-vitro enzymology and enzyme kinetics knowledge to clinical pharmacokinetics problems. In recognition of her original and significant scientific contributions as well as future strong potential in the field of foreign compound metabolism and disposition, ISSX proudly bestows the 2014 North American New Investigator Award in Honor of James R. Gillette on Nina Isoherranen. Award Presentation and Lecture: Tuesday, October 21, 2014 | 2:00 p.m. – 3:00 p.m. | Continental Ballroom
Issue 3, 2014
/ISSX Newsletter / 11
If you’re working on or studying the effects of drug metabolism and pharmacokinetics, then this reference is for you!
N
EW
Handbook of
Metabolic Pathways of Xenobiotics Editors:
Professor Dr. Philip W. Lee, Dr. Hiroyasu Aizawa, Dr. Lawrence L. Gan, Dr. Chandra C. Prakash, Professor Dafang Zhong
Discover the metabolic fate of xenobiotics in biological systems and the environment with this essential introduction, guide and catalogue, covering • Current topics in the metabolism of xenobiotics • Techniques and methods used in establishing metabolic pathways • Biotransformation pathways presented as a catalogue of short articles • Over 450 detailed examples of xenobiotics and their fate in animals and plants
5 Volume Print Edition February 2014 £950.00 / €1220.00 / $1495.00 ISBN: 978-0-470-74910-4
• Chemical and biological fate data in a rare single source
Now available online!
The Handbook of Metabolic Pathways of Xenobiotics is also available as a five volume print set, order your copy at www.wiley.com/go/xenobiotics
14-62055
The Handbook of Metabolic Pathways of Xenobiotics is now available online – assess the content for yourself, download sample content and start a free trial at wileyonlinelibrary.com/ref/xenobiotics. Why not recommend that your librarian requests a free trial for your institution?
Make Plans to Attend the 13th European ISSX Meeting June 22-25, 2015 The University of Strathclyde • Glasgow, Scotland
Features of this Meeting The meeting will include short courses, keynote lectures delivered by leading researchers, parallel sessions on a wide range of topics, poster sessions, awards presentations, and a trade exhibition. There will be multiple opportunities for attendees to enjoy scientific and social interaction with friends and colleagues in a purpose-built conference facility in the centre of Glasgow.
submission, how to nominate a deserving candidate for the European Scientific Achievement Award or European New Investigator Award in Honor of Karl J. Netter, registration and exhibition information, and much more! Be certain to include this outstanding scientific meeting in an easily accessible location in Europe in your department’s budget and make plans to join us in Glasgow, Scotland June, 22-25, 2015. The abstract submission site for this meeting opens on October 1, 2014. Watch your email for more information!
Meeting Organizing Committee Co-Chairs: Ann Daly, Newcastle University Roland Wolf, University of Dundee Meeting Organizing Committee:
Meeting Venue The 13th European ISSX Meeting will convene in a new state-of-the-art facility on the campus of the University of Strathclyde, which is located in centre city Glasgow. Both university housing and business hotels will be available for attendees.
Watch for communications from ISSX regarding abstract
www.issx.org/awards/nominations The 2015 European Scientific Achievement Award and the 2015 European New Investigator Award, in Honor of Karl J. Netter, will be presented at the 13th European ISSX Meeting in June 2015 in Glasgow, Scotland. The awards will include travel support to the meeting. Nominate a deserving member today! The submission deadline is April 10, 2015.
/ISSX Newsletter / 13
There is much to see in and around Glasgow. Stately homes and museums like the Burrell Collection and Kelvingrove Art Gallery & Museum should not be missed. With Loch Lomond just half an hour away, there is plenty of breathtaking scenery to enjoy too. Glasgow also has great shopping and inspiring architecture, making it a wonderful city to visit. It provides an excellent launching point for exploring the other many sights to see in Scotland.
13th EUROPEAN ISSX MEETING AWARDS
Issue 3, 2014
Glasgow is easily accessed from two main airports close to the city: Glasgow International Airport and Glasgow Prestwick International Airport. Edinburgh Airport is only 40 miles away.
John Hayes, University of Dundee Brian Houston, University of Manchester Neil Kitteringham, University of Liverpool Michael McMahon, University of Dundee Richard Meehan, University of Edinburgh Munir Pirmohamed, University of Liverpool Colin Suckling, University of Strathclyde Geoff Tucker, University of Sheffield Michael Voice, Cypex, Dundee Heather Wallace, University of Aberdeen Matt Wright, Newcastle University
ISSX depends on the support of its members to help us organize our educational activities and to sustain our operations. Please respond to the membership dues notices that will be distributed in late October. Membership dues remain unchanged and go far towards helping us achieve our goals.
ISSX members have access to a variety of exclusive benefits including: A Subscription to the ISSX Newsletter -‐ Members receive a quarterly newsletter that highlights Society news, member spotlights, upcoming meetings, late breaking scientific news, and much more. Reduced Registration Fees -‐ Members receive significant discounts on registration fees for all ISSX meetings and workshops. Recorded Educational Content -‐ New in 2015 -‐ Members can access recorded content online at a reduced members-‐only rate. Abstract Presentations -‐ Members have the opportunity to submit abstracts to present their work with other leaders in the field at ISSX meetings. Searchable Meeting Abstracts -‐ Members may perform searches for and cite abstracts from past ISSX meetings. Networking Opportunities -‐ Meet with other local and international leaders interested in DMPK. Society Awards Program -‐ Only ISSX members are eligible for the prestigious Scientific Achievement Awards presented at our regional meetings. Travel Grants -‐ Eligible members may apply for travel assistance to attend ISSX regional and international meetings. Membership Directory -‐ Our searchable online membership directory makes connecting with fellow researchers convenient. Special Journal Subscription Discounts -‐ Members receive special subscription discounts to multiple scientific journals, including Drug Metabolism Reviews, Annual Review of Pharmacology and Toxicology, and many more. Hold Office and Serve on a Committee -‐ Holding a position of leadership in ISSX is a tremendous opportunity to serve your peers worldwide, to develop important skills, help set the work plan of a prestigious international scientific society, and be recognized as a leader volunteer of an international scientific society. Vote in ISSX Elections -‐ Helping to choose the future leaders of ISSX sets the path of our organization and provides you the opportunity to elect those who best represent your interests. Most of all, your membership indicates your support of our mission to advance the understanding of the interactions of medicines and chemicals with living systems and helps sustain our program of operations. Please support ISSX by renewing your membership today!
www.issx.org/membership/renew
ISSX Welcomes New 2014 Members!
Continued on next page
/ISSX Newsletter / 15
William Hedrich, Univeristy of Maryland, Baltimore, United States Jamie Henshall, UCB, United Kingdom Jennifer Hibma Hilliary Hodgdon, FORUM Pharmaceuticals, United States Ethan Hoffmann, SAGE Therapeutics, United States Chelsea Hosey, UCSF, United States Andrea Hubeny, Germany Jade Huguet, Canada C. Anthony Hunt, University of California, San Francisco, United States Tomomi Ito, CMIC, Japan Swati Jaiswal, CSIR-Central Drug Research Institute, India Hyeon-Uk Jeong Wenjie Jiang, Optivia Biotechnology Inc, United States Amanda Johnson, United States Tomoko Jomura, TOYO GOSEI CO., LTD., Japan Barbara KĂźppers-Munther, Cellartis AB / Cellectis AB, Sweden Tetsuya Kaneko, Oita University Hospital, Japan Rudiger Kaspera, AstraZeneca, United States Steve Kemperr Ryota Kikuchi, Abbvie Inc., United States Ju Hyun Kim Eun Nam Kim Masaki Kobayashi, Hokkaido University, Japan Hamed Kohan, Albany College of Pharmacy and Health Sciences, United States Tae Yeon Kong Nora Krutz, University Trier, Germany Vineet Kumar, University of Washington, United States Jeevan Kunta, Janssen R&D LLC, United States Soon Sang Kwon Jason Labutti, Pfizer, United States John Lang, NSF Health Sciences, United Kingdom Shuaizhang Li, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, China Ming Li, University of Groningen, Netherlands
Issue 3, 2014
Khondoker Alam, University of Oklahoma Health Sciences Center, United States Bukola Aluko, Ekiti State University, Ado-Ekiti, Nigeria Yusuke Aratsu, Japan Tobacco Inc., Japan Frauke Assmus, Manchester University, Manchester Pharmacy School, United Kingdom Chris Badenhorst, North-West University, South Africa Jason Baik, Optivia Biotechnology Inc., United States Michael Baldwin, Theravance, United States John Barr, Washington State University, United States Martin Carnerup, LEO Pharma A/S, Denmark Hardik Chandasana, CSIR-Central Drug Research Institute, India Satish Cheepala, St. Jude Children’s Research Hospital, United States Lei Ci, Biogen Idec, United States Wenqi Cui, University of Kansas, United States Shyam Das, Tata Consultancy Services, India Carwyn Davies, GlaxoSmithKline, Australia Gauri Deshmukh, Genentech, Inc., United States Yeshwant Dogra, CSIR-Central Drug Research Institute, India Prashant Dogra, University of New Mexico Health Sciences Center, United States Tanda Dudenkov, Mayo Clinic, United States Stephen Dueker, Sivvon Biolabs, United States Carsten Ehrhardt, Trinity College Dublin, Ireland Sara Eng, Gilead Sciences Inc., United States Ili Erdemir, Sanofi, United States Eric Evangelista, University of Washington, United States Taleah Farasyn, University of Oklahoma Health Sciences Center, United States Kevin Forbes, Sage Labs, Inc., United States Kevin Ford, Genentech, United States Junji Furukawa Philip Gardiner, AstraZeneca, Sweden Sashi Gopaul, GlaxoSmithKline, United States Richard Grater, Biogen Idec, United States Sophie Gravel Helen Gu, Novartis Pharmaceuticals, United States Cen Guo, UNC Eshelman School of Pharmacy, United States Dong Guo, University of Maryland, United States
/ISSX Newsletter / Issue 3, 2014 16
Guannan Li Chien-Ming Li, Optivia Biotechnology, United States Christine Lin Hua Yang Lin, Holy Stone Healthcare Co., Ltd., Taiwan Kwang Hyeon Liu, Kyungpook National University, Korea Cho-Ming Loi, Pfizer, Inc,. United States Yang Lu, University of North Carolina, United States Bingli Ma, Takeda, United States Jialin Mao, Genentech, Inc., United States Thanga Mariappan, Syngene International Ltd., India Svetlana Markova, MyoKardia, United States Michael Martin, University of California, San Francisco, United States Stephanie Martinez, University of Manitoba, Canada Mark McKeage, University of Auckland, New Zealand Michael McMahon, University of Dundee, United Kingdom Hong Mei, United States Karsten Menzel, Merck & Co., United States Veronique Michaud, CRCHUM, University of Montreal, Canada Ryan Murray, Rigel Pharmaceuticals, Inc., United States Khine Myint Tsutomu Nakamura, Himeji Dokkyo University, Japan Rhonda Newman, Thermo Fisher Scientific, United States Chan Way Ng, National University of Singapore, Singapore Line Olsen, University of Copenhagen, Denmark Shogo Ozawa, Iwate Medical University, Japan Kamalavenkatesh P, Syngene International Ltd., India Sarah Pass, Huntingdon Life Sciences, United Kingdom Pornteera Pawijit, National University of Singapore, Singapore Anders Pedersen, Univerisity of Copenhagen, Denmark Elyse Petrunak, University of Kansas, United States Poorna Piyathilaka, University of Sri Jayewardenepura, Sri Lanka Joseph Polli, University at Buffalo, SUNY, United States Sharon Presnell, Organovo, United States Ganesh Rajaraman, AbbVie, Inc., United States Adrian Ray, Gilead Sciences, Inc., United States Octavio Reyes-Hernández, Hospital Juárez de México, Mexico Cliff Rowe, CN Bio innovations, United Kingdom Daniel Ryan, Human BioMolecular Research Institute, United States Punam Sandhu, Merck, Sharp & Dohme, United States Yuichiro Sato, Astellas Pharma Inc., Japan Tiffany Scharadin, UC Davis Health System, United States
Ryan Seguin, University of Washington, United States Matthew Shipton, Hurel Corporation, United States Monica Sierra Martínez, Hospital Juárez de México, Mexico Andrew Smith Harmen Steele, University of Montana, United States Paul Steinberg, Eckert & Ziegler Vitalea Science, United States Rebecca Sullivan, University of Manchester, United Kingdom Lei Sun, Alkermes, United States Ryosuke Takahashi, Hitachi, Ltd., Japan Isha Taneja, CSIR - Central Drug Research Institute, India Lan Tang, Southern Medical University, China Erica Tien, UCONN School of Pharmacy, United States Kohei Togami, Hokkaido Pharmaceutical University, Japan Katalin Toth, Hungarian Academy of Sciences Research Centre for Natural Sciences, Hungary Annalena Ungell, UCB Biopharma SPRL, Belgium Vincent van der Mark, Academic Medical Center, Netherlands Suramya Waidyanatha, NIEHS/NIH, United States Lai Wang, Novartis, United States Zhiying Wang, University of Kansas, United States Wei Wang, Hong Kong Li Wang, United States Chunxue Wang, Vanderbilt University, United States Angela Wehr, Biogen Idec, United States Ping Xiong, GlaxoSmithKline, United States Fang Yan Sihyung Yang, University of Kansas, United States Francis Yoshimoto, United States Walter Yu, Medivation, United States Yu Yu, National University of Singapore, Singapore Qin Yue, Novartis, United States Nicole Zane, UNC Eshelman School of Pharmacy, United States Zufei Zhang, University of Washington Seattle, United States Qiang Zhang, Incyte Corporation, United States Ting Ting Zhang, Abbvie Bioresearch Center, United States Xuexiang Zhang, Optivia Biotechnology Inc., United States Guo Zhong, University of Florida, United States Haojie Zhu, University of Michigan College of Pharmacy, United States Maike Zimmermann, University of California Davis, United States
Change of Address
ISSX Newsletter is published quarterly in the spring, summer, autumn, and winter. For information concerning advertising in this publication, including rates and specifications, please visit www.issx.org or contact information@issx.org.
If your mailing address, telephone, fax number, or e-mail has changed or will change, please let us know as soon as possible. You may update your contact information at any time using the online membership directory, which you can access in the Member Only section of the Web site. If you have forgotten your username and/or password, please contact information@issx.org.
Advertise with ISSX in the quarterly ISSX Newsletter. Rates and additional advertising opportunities are available at www.issx.org/advertising2014.
Deadline for the submission* of material to the ISSX Office: ISSUE
MATERIALS DEADLINE
RELEASE DATE
Issue 4, 2014
November 14, 2014
December 2014
*
Subject to change
Editor Dr. Allen Cato, III Cato Research, LTD 6480 Weathers Place, Suite 104 San Diego, California 92121 USA Telephone: +1-858-452-7271 Fax: +1-858-452-7784 E-mail: jcato@cato.com
Advertise with ISSX The quarterly ISSX Newsletter is an online publication featuring Society updates, scientific articles of interest, book reviews, summaries of ISSX meeting proceedings, and more. This publication is designed to update the ISSX membership on the activities and events of the organization and to provide an information forum. Not only is the ISSX Newsletter promoted directly to all ISSX Members, but, as of 2012, it is also available to anyone who visits the ISSX Web site. Visit www.issx.org/advertising2014 today!
ISSX CAREER CENTER Searching for experts in the field of drug metabolism, pharmacokinetics, pharmacodynamics, and other related areas? The ISSX Career Center job board is your premier resource to find skilled applicants. • Create your Company Profile free of charge and explain the organization and work environment in detail. • When your positions are advertised on the ISSX Career Center, an e-mail advertising the position is sent automatically to job seekers who have requested notifications about opportunities matching their search criteria. • Browse résumés for free and pay only for the résumés that you select. Post your jobs online today! When you use the ISSX Career Center, you ensure that your open positions are advertised in the right place. Visit www.issx.org/careercenter.